In the tumour microenvironment (TME), immunogenic cell death (ICD) plays a major role in
stimulating the dysfunctional antitumour immune system. Chronic exposure of damage …

Cancer immunotherapies that train or stimulate the inherent immunological systems to
recognize, attack, and eradicate tumor cells with minimal damage to healthy cells have …

Immunotherapy with immune checkpoint blockade (ICB) has shown limited benefits in
hepatocellular carcinoma (HCC) and other cancers, mediated in part by the …

As immunogenic cell death (ICD) inducers initiating antitumor immune responses, certain
chemotherapeutic drugs have shown considerable potential to reverse the …

Intratumoral immunosuppressive microenvironment (ISM) remains the dominant limitation to
disable oncological immunotherapy such as immunogenic cell death (ICD). To resolve the …

Cancer cells have various immune evasion mechanisms that resist the immune cells by
reprogramming the tumor microenvironment (TME), such as programmed death-ligand 1 …

Chemoresistance of cancer cells is a major problem in treating cancer. Knowledge of how
cancer cells may die or resist cancer drugs is critical to providing certain strategies to …

To effectively build on the recent successes of immune checkpoint blockade, adoptive T cell
therapy and cancer vaccines, it is critical to rationally design combination strategies that will …

Though we crossed many milestones in the field of medicine and health care in eradicating
some deadly diseases over the past decades, cancer remained a challenge taking the lives …

Immune checkpoint blockade is a promising approach for cancer immunotherapy, but many
patients do not respond due to the immunosuppressive tumor microenvironment (ITM) …